NEW RESEARCH:
Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea & PANDAS
CLINICIAN RESOURCES
PPN maintains the most up to date clinical guidelines for PANDAS and PANS. Guidelines will always be based on published information and further refined and explained by the Diagnostics & Therapeutics Committee.
PPN Treatment Options aim to provide the breadth of potential therapies for PANDAS and PANS, updated for the latest research and experience of clinicians. There are a variety of treatment options available.
“Seeing Your First Child with PANDAS/PANS” is a medical guide consisting of: overview and current theories, PANS diagnostic criteria, PANS workup recommendations, and setting medical and family expectations.
CORNONAVIRUS (COVID-19)
Coronavirus (COVID-19) updates for PANDAS/PANS patients will be made available by the PPN.
NEW: Survey of the PANS/PANDAS Patient Population during the COVID-19 Pandemic
NEW YALE RESEARCH
Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity
“These findings provide strong evidence for striatal CINs as a critical cellular target that may contribute to pathophysiology in children with rapid-onset OCD symptoms, and perhaps in other conditions.”
NEW STANFORD RESEARCH
Association of PANS With Microstructural Differences in Brain Regions Detected via Diffusion-Weighted MRI
“This study identifies cerebral microstructural differences in children with PANS in multiple brain structures, including the deep gray matter structures (eg, the thalamus, basal ganglia, and amygdala)”
FRONTIERS IN PSYCHIATRY
Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea and PANDAS
“Our results suggest that the panel of four antineuronal antibodies and CaMKII activation assays successfully identify acute illness in PANDAS, providing opportunities for rapid and accurate diagnosis and treatment.”
CME LEARNING OPPORTUNITY
Learn the latest evidence-based strategies for early and accurate diagnosis, individualized treatment, and management of PANDAS/PANS. Watch the complimentary,on demand webinar, An Overview for Diagnosing and Treating PANS/PANDAS, presented by Susan E. Swedo, MD, Scientist Emeritus at the National Institute of Health.
PANS/PANDAS RESEARCH AND LITERATURE
OUR MISSION
The PPN mission is to maintain the industry standard PPN Guidelines for Diagnostics and Therapeutics, foster continuous education and communication within the multi-disciplinary medical community and to sponsor research for developing diagnostic tests, treatment protocols and a cure for PANDAS/PANS within this generation.
MEDICAL PROFESSIONALS: BECOME A MEMBER OF PPN
It’s free to become a member of the PPN. Benefits include:
► Communicate and ask questions to your peers.
► Receive email alerts on new research, guidelines, and treatment protocols
► Option to be recognized as a practitioner who works with PANS/PANDAS patients
► Receive occasional members only benefits
CHANGE THE COURSE OF MENTAL ILLNESS WITHIN A GENERATION
PPN’s goal is to help medical professionals understand, diagnose and treat PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) by providing to them quality research, diagnostic and treatment tools. Your donation dollars will not only help maintain PPN’s tools, but will help further prove that the immune system can cause such psychological distress.
